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OBJECTIVE—To test whether brain fatty acid uptake is en-
hanced in obese subjects with metabolic syndrome (MS) and
whether weight reduction modiﬁes it.
RESEARCH DESIGN AND METHODS—We measured brain
fatty acid uptake in a group of 23 patients with MS and 7
age-matched healthy control subjects during fasting conditions
using positron emission tomography (PET) with [
11C]-palmitate
and [
18F]ﬂuoro-6-thia-heptadecanoic acid ([
18F]-FTHA). Sixteen
MS subjects were restudied after 6 weeks of very low calorie diet
intervention.
RESULTS—At baseline, brain global fatty acid uptake derived
from [
18F]-FTHA was 50% higher in patients with MS compared
with control subjects. The mean percentage increment was 130%
in the white matter, 47% in the gray matter, and uniform across
brain regions. In the MS group, the nonoxidized fraction mea-
sured using [
11C]-palmitate was 86% higher. Brain fatty acid
uptake measured with [
18F]-FTHA-PET was associated with age,
fasting serum insulin, and homeostasis model assessment
(HOMA) index. Both total and nonoxidized fractions of fatty acid
uptake were associated with BMI. Rapid weight reduction de-
creased brain fatty acid uptake by 17%.
CONCLUSIONS—To our knowledge, this is the ﬁrst study on
humans to observe enhanced brain fatty acid uptake in patients
with MS. Both fatty acid uptake and accumulation appear to be
increased in MS patients and reversed by weight reduction.
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A
lthough the brain does not use free fatty acids
(FFAs) as an energy source, recent evidence
suggests that FFAs and, speciﬁcally, their inter-
mediates could have a key role in the central
control of energy balance regulation and feeding (1–5).
Both brain FFA uptake and metabolism are currently
insufﬁciently deﬁned, whereas the importance of FFAs in
the pathogenesis of metabolic syndrome (MS) is demon-
strated widely in other organs (6,7). Animal studies have
demonstrated that hypothalamic sensing of circulating
fatty acids in general is believed to be important in
controlling nutrient intake and, thus, energy balance. For
example, Pocai et al. (5) showed that manipulation of
central hypothalamic FFA metabolism normalizes energy
and glucose homeostasis in overfed rats. These regulatory
processes are difﬁcult to address in humans in vivo, and
most data in this regard have been demonstrated in small
animals (1,4,5,8). More work is needed to clarify the
mechanisms behind the complex hypothalamic regulatory
circuitry that regulates energy expenditure and feeding
behavior.
Positron emission tomography (PET) and other meth-
ods have been used to evaluate the fate of long-chain
saturated fatty acid carbon-labeled-palmitate (9–12). PET
provides a method for noninvasive, quantitative, and re-
gional measurement of FFA uptake, thus making it ideal
for studying metabolism in different tissues (13). The
status of brain FFA metabolism in MS is currently un-
known. Therefore, our aim was to use PET to examine
possible difference in the brain FFA-uptake rates between
MS patients and healthy individuals.
RESEARCH DESIGN AND METHODS
Subjects. Twenty-three subjects with MS (age 43  7 years, BMI 33.6  4.0
kg/m
2, 8 men and 15 women) and 7 age-matched healthy men (age 42  11
years, BMI 26.8  2.5 kg/m
2) (Table 1) were recruited, mostly from an
occupational healthy service clinic. Healthy patients were nonobese and had
normal oral glucose tolerance test results, whereas the 23 MS patients had MS
according to the current International Diabetes Federation criteria (14) (Table
2). According to the criteria, a person deﬁned as having MS must have central
obesity, deﬁned as increased waist circumference plus at least two other
additional criteria (raised triglycerides/blood pressure/fasting glucose or
reduced HDL). Subjects were told to use no alcohol during the study period.
Smoking was an exclusion criterion. Only 1 of 23 subjects with MS used
medication (ACE inhibitor for blood pressure). Written informed consents
were obtained after explaining the purpose and potential risks of the study to
the subjects. The study protocol was approved by the Ethics Committee of the
Hospital District of Southwest Finland and conducted according to the
principles of the declaration of Helsinki.
Study design. The study was designed to assess 1) the differences between
MS patients and healthy individuals at baseline, and 2) the effect of a very low
caloric diet (VLCD) in MS patients. Two PET studies were performed, ﬁrst
with [
11C]-palmitate, and thereafter with [
18F]ﬂuoro-6-thia-heptadecanoic acid
([
18F]-FTHA), either during the same day or on separate days within 1 week.
A subgroup of patients with MS (n  16) were prescribed a VLCD. All daily
meals were replaced by diet products for 6 weeks (Nutrifast, Leiras, Finland,
2.3 MJ (megajoule), 4.5 g fat, 59 g protein, and 72 g carbohydrate per day).
After the diet there was a 1-week recovery period with an isocaloric diet to
avoid catabolic state. The isocaloric diet was based on estimations of energy
expenditure and was introduced by a physician. The assessments using PET
were repeated. Magnetic resonance images were obtained for anatomical
reference.
Production and nature of radiotracers. The production of [
11C]-palmitate
(half-life 20.4 min) (15) and the production of [
18F]-FTHA (half-life 109 min):
(16) are described elsewhere. The radiochemical purity of the ﬁnal product
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18F]-FTHA ([
18F]ﬂuoro-6-thia-heptadecanoic acid)
is a long-chain FA analog that has a sulfur-substitution in the sixth carbon and
a radioactive ﬂuorine-18 label. [
18F]-FTHA which is taken up by tissues and
subsequently either enters mitochondria or is incorporated into complex
lipids (16). In mitochondria, [
18F]FTHA undergoes initial steps of -oxidation
and is thereafter trapped as further -oxidation is blocked by its sulfur
heteroatom (17). Because of these properties, [
18F]-FTHA provides optimal
target-to-background signal in PET images.
In vivo validation of biodistribution of [
18F]-FTHA and [
13C]-palmitate
in pig brain. To validate the biodistribution of both [
18F]-FTHA and [
13C]-
palmitate in brain, we used data from in vivo pig [
18F]-FTHA biodistribution
study (18), and completed the study by analyzing the biodistribution of stable
[
13C]-palmitate from frozen brain samples obtained from the same animals.
The study protocol and analysis of [
18F]-FTHA has been described in detail
elsewhere (18), and the palmitate information is provided in an online
appendix in an online appendix available at http://diabetes.diabetesjournals.
org/cgi/content/full/db09-0138/DC1. The results are provided in Table 3.
Roughly 62% from [
13C]-palmitate and 69% from [
18F]-FTHA was found in brain
lipids. Most of the [
13C]-palmitate in brain lipids was found in phospholipids,
and only trace amounts were found in triglycerides and fatty acids. [
18F]-FTHA
was found mostly in triglycerides.
PET studies. Patients were scanned in the fasting state, and they refrained
from drinks containing caffeine, smoking, and all medications for 12 h before
the PET scan. Studies were performed in a supine position. Two catheters
were inserted in the antecubital veins of different arms: one for saline infusion
and tracer injection, and another for blood sampling. [
11C]-palmitate scan was
performed before [
18F]-FTHA. [
18F]-FTHA scan was started after 7 half-lives of
[
11C]-palmitate had occurred. The mean doses of injected [
11C]-palmitate and
[
18F]-FTHA were 312  148 MBq and 182  17 MBq. With [
11C]-palmitate,
dynamic brain scanning started immediately after injection (frames 815s,
230s, 2120s, 1180s, and 2300s). Healthy individuals and MS patients not
subscribed to VLCD were scanned with [
18F]-FTHA immediately after injec-
tion (frames 360s, 1120s, 5300s, 2600s). For MS patients subscribed to
VLCD, [
18F]-FTHA scanning started 70 min after injection and was static (600
s). During the scans, arterialized venous blood samples were drawn for the
determination of plasma radioactivity (0, 15, 30, 45, 60, 75, 90, 105 s, and 2, 3,
4, 5, 10, 15, 20, 30, 40, 50 min for both [
11C]-palmitate and [
18F]-FTHA, and
additional time points of 60, 70, 80, and 90 min for [
18F]-FTHA). Serum FFAs,
insulin and glucose concentrations were measured at 0, 10, and 30 min after
the [
11C]-palmitate injection, and 0, 30, 60, and 90 min after the [
18F]-FTHA
injection.
Image acquisition, processing, and corrections. Most studies were per-
formed using GE Discovery PET-CT STE (GE, Medical Systems, Milwaukee,
WI), but because of the short half-life of [
11C]-palmitate, Siemens ECAT HR
(Knoxville, TN) and GE Advance (GE Medical Systems, Milwaukee, WI) were
in use when this tracer was divided. The second study was scanned with same
camera-protocol as the ﬁrst study. Data were corrected for dead-time, decay,
and photon attenuation. PET images were reconstructed in GE Advance using
a 128  128 matrix with a 30-cm ﬁeld of view (FOV) in three-dimensional (3D)
mode and Filtered Back Projection (FBP) reconstruction, in Siemens HR
using 128  128 matrix with zoom two (28.8 cm FOV) in 3D mode and FBP
reconstruction and in PET-CT using 128  128 matrix with 35 cm FOV in 3D
mode and Iterative Ordered Subset Expectation Maximization (OSEM) recon-
struction (VUEPoint).
Calculation of the parametric fractional uptake rate image. Brain
fractional uptake indexes for [
11C]-palmitate and [
18F]-FTHA were calculated
by dividing the brain radioactivity by the integral of the plasma unmetabolized
radioactivity curve at 15 min. The modeling gives results that are independent
of the injected tracer dose. The fractional uptake rate (FUR) image from
dynamic brain scanning was calculated from 10–20 min.
Analysis of PET images. The detailed description of regional and voxel level
PET image analyses and statistical analyses of regional FUR estimates are
provided in the online appendix. All values are expressed as mean  SD.
P values  0.05 are considered statistically signiﬁcant.
Biochemical analyses. Details of biochemical analyses are provided in the
online appendix.
Statistical analysis of biochemical and anthropometric data. Student t
test was used in baseline to compare results between MS patients and the
control group. A paired Student t test was used to compare changes in the MS
group before and after VLCD. Correlations were analyzed using SAS Enter-
prise Guide 4.1 (4.1.0.471; SAS Institute, Cary, NC). The normality of variables
was assessed by the Shapiro-Wilkins test. Variables with normal distribution
were calculated using Pearson correlation, and non-normal Spearman corre-
lation was used. All values are expressed as mean  SD. P values  0.05 are
considered statistically signiﬁcant.
RESULTS
Metabolic characteristics during the study. Compared
with the healthy control subjects, patients with MS had
higher fasting plasma glucose concentrations (Table 1),
but otherwise no signiﬁcant differences in oral glucose
tolerance test (OGTT) results between healthy control
patients and MS patients were found. After VLCD, subjects
with MS lost weight 11.1 kg (range 7.2–15.4 kg, P 
0.0001), whereas total cholesterol (P  0.0001), LDL (P 
TABLE 1
Baseline anthropometric and metabolic characteristics
Metabolic
syndrome Healthy P value
n (female/male) 23 (15/8) 7 (0/7)
Age, years 43  74 2  11 NS
Weight, kg 98.7  12.1 84.9  8.6 0.009
BMI, kg/m
2 33.6  4.0 26.8  2.5 0.0003
Fasting glucose, mg/dl 109.8  12.6 97.2  3.6 0.02
OGTT glucose, 60 min,
mg/dl 156.6  54.0 176.4  12.6 NS
OGTT glucose, 120 min,
mg/dl 129.6  52.2 100.8  19.8 NS
Fasting insulin, mU/l 6.8  2.6 3.9  1.6 0.02
Total cholesterol, mg/dl 185.6  34.8 170.1  23.2 NS
HDL cholesterol, mg/dl 50.3  11.6 50.3  7.7 NS
Triglycerides, mg/dl 115.1  53.1 88.6  53.1 NS
LDL cholesterol, mg/dl 112.1  34.8 100.5  23.2 NS
HOMA index 1.8  0.7 0.9  0.4 0.02
Data are mean  SD unless otherwise indicated. Fasting insulin
values are from PET-scanning day. Homeostasis model assessment
(HOMA) index calculated (fasting insulin  fasting glucose)/22.5. P
values obtained from Student t test. NS, not signiﬁcant.
TABLE 2
Characteristics of MS group according to International Diabetes
Federation criteria
Metabolic
syndrome
n (female/male) 23 (15/8)
Increased waist circumference (women 80 cm,
men 94 cm) 23 (15/8)
Raised triglycerides (150.6 mg/dl) 4 (2/2)
Lowered HDL cholesterol (women 49.9 mg/dl;
men 39.8 mg/dl ) 7 (5/2)
Raised systolic blood pressure (130 mmHg) 14 (10/4)
Raised diastolic blood pressure (85 mmHg) 15 (11/4)
Raised fasting plasma glucose (100.8 mg/dl) 18 (12/6)
TABLE 3
Percentage distribution of brain 	
13C
-palmitate and 	
18F
-FTHA
uptake in vivo
Radioactivity
distribution from
total lipids  Aq* 	
13C
-palmitate 	
18F
-FTHA
Paired
Student
t test
Aq* % 37.7  0.0† 30.9  9.7 NS
All lipids % 62.3  0.0 69.1  9.7 NS
Triglycerides % 0.6  0.2 53.4  11.3 P  0.0001
Fatty acids % 2.2  0.1 6.3  3.3 NS
Phospholipids % 59.4  0.3 9.4  3.2 P  0.0001
Number of pigs (	
18F
-FTHA n  8, 	
13C
-palmitate n  6). *Hydro-
philic phase. †The hydrophilic phase of 	
13C
-palmitate is estimated
based on tracer brain distribution curve at 3-h time point, published
by Miller et al. (11). NS, not signiﬁcant.
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4). Changes in fasting plasma glucose concentration and in
fasting insulin after VLCD were signiﬁcant. The percentage
decrease in fasting insulin was 37.4%.
Brain fatty acid tracer accumulation over time. After
injection, [
18F]-FTHA radioactivity in the brain increased
over time (Fig. 1A). As shown previously, plasma [
18F]-
FTHA and [
11C]-palmitate concentration decreased
quickly after injection (9,19,20). The increase in tissue
radioactivity over time with [
18F]-FTHA reﬂects label
trapping (Fig. 1). As shown in an example of brain image
after [
18F]-FTHA injection (Fig. 2), radioactivity was high-
est in the thalamus (the two largest gray matter nuclei in
the center of the transaxial image), followed by high
uptake in the basal ganglia and throughout the cerebral
cortex.
Brain FFA uptake in healthy subjects and patients
with MS. When brain FFA uptake was measured using
[
18F]-FTHA and the values of plasma FFA concentration
during PET, the brain FFA uptake was signiﬁcantly higher
in patients with MS compared with healthy subjects (Fig.
2). The mean percentage increase was 130% in the white
matter and 47% in the gray matter, and respective
standardized effect sizes were 1.83 and 0.88. The main
effect of the group was signiﬁcant in the repeated mea-
sures ANOVA (rmANOVA) (F  7.38, P  0.012), whereas
no effect from the scanner was observed. In addition, the
group  region interaction was signiﬁcant (F  5.35, P 
0.016), indicating that the group difference in [
18F]-FTHA
uptake was not uniform across brain regions. Regional
ANOVAs indicated signiﬁcant group differences in all
regions: white matter (P  0.001), anterior cingulate (P 
0.038), parietal (P  0.015), temporal (P  0.015) and
prefrontal cortex (P  0.020), amygdala-hippocampal
complex (P  0.014), striatum (P  0.019), and hypothal-
amus (P  0.007). The mean percentage increment in the
hypothalamic area was 52% among the subjects with MS
compared with healthy subjects. No scanner effects were
seen in any region. A marked elevation was also found in
the brain uptake of [
11C]-palmitate in patients with MS
when compared with healthy controls (Fig. 2). The aver-
age increase was 83.8% in the white matter and 87.7%
in the gray matter. The standardized effect sizes were of
large magnitude, 1.24 in both the white and gray matter.
The rmANOVA also demonstrated a signiﬁcant main effect
of group (P  0.017). Because different PET-scanners were
used in this study, we wanted to test whether the use of
different PET-scanners would have an impact on the
ﬁndings. The rmANOVA demonstrated no effects of the
scanner (P  0.959). The group  region interaction was
also signiﬁcant (P  0.016), suggesting that elevation of
[
11C]-palmitate uptake in the brain in patients with MS
might vary across brain regions. In ANOVA models, pre-
dicting regional [
11C]-palmitate uptake with group status
and scanner demonstrated signiﬁcant group differences in
all brain regions: white matter (P  0.021), anterior
cingulate (P  0.028), parietal (P  0.011), temporal (P 
0.013) and prefrontal cortex (P  0.015), amygdala-hip-
pocampal complex (P  0.016), striatum (P  0.029) and
hypothalamus (P  0.016). The mean percentage change in
hypothalamic area was 88% among the subjects with MS
compared with healthy subjects. The uptake of [
18F]-FTHA
correlated positively with [
11C]-palmitate in all analyzed
brain areas, and all the correlations were statistically
signiﬁcant. For the hypothalamus, the correlation r value
was 0.58 (P  0.003).
The effect of dieting on brain FFA uptake. There was
a substantial reduction in the brain uptake of [
18F]-FTHA
in patients with MS after VLCD (Fig. 3). The mean percent-
age decrease was 17.5% in the white matter and 17.6%
in the gray matter. In the rmANOVA, the main effect of
repetition was statistically signiﬁcant (P  0.010), whereas
the repetition  region interaction was not (P  0.099).
The latter suggests that the decrease in tracer uptake was
TABLE 4
Anthropometric and metabolic characteristics after VLCD
Before VLCD After VLCD P value
Weight, kg 100.4  11.7 89.4  11.1 0.0001
BMI, kg/m
2 34.0  3.9 30.2  3.9 0.0001
Fasting glucose, mg/dl 180.0  10.8 102.6  9.0 0.02
OGTT glucose, 60
min, mg/dl 138.6  39.6 117.0  36.0 NS
OGTT glucose, 120
min, mg/dl 111.6  27.0 104.4  23.4 NS
Fasting insulin, mU/l 6.8  2.6 4.6  2.2 0.0001
Total cholesterol,
mg/dl 189.5  30.9 143.1  23.2 0.0001
HDL cholesterol,
mg/dl 50.3  11.6 50.3  7.7 NS
Triglycerides, mg/dl 106.3  44.3 79.7  26.6 0.002
LDL cholesterol,
mg/dl 116.0  30.9 81.2  19.3 0.0001
HOMA index† 1.8  0.7 1.2  0.7 0.0002
Free fatty acids,
mmol/l 0.61  0.17 0.56  0.14 NS
Data are mean  SD. Number of subjects  16 (11 females and 5
males). †HOMA index calculated (fasting insulin  fasting glucose)/
22.5; fasting insulin values are from PET-scanning day. P values
obtained from paired Student t test. NS, not signiﬁcant; VLCD, very
low calorie diet.
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FIG. 1. An example of a time course of brain tissue radioactivity after
intravenous injection of [
18F]-FTHA and [
11C]-palmitate from one
nonobese healthy subject and one obese subject with MS. The values
are given as standardized uptake values (SUVs), and values are nor-
malized to the dosage (MBq), and body weight (kg). The resulting SUV
value has been multiplied with individual blood FFA level. The increase
in brain radioactivity over time with [
18F]-FTHA reﬂects tracer trap-
ping. Black circles, healthy; white circles, MS.
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errors, regional changes were not formally assessed. This
result was conﬁrmed using a voxel-based mapping analy-
sis (Fig. 3). The change in [
11C]-palmitate uptake was
highly variable between individuals, with the average
across regions ranging from 37% to 210% and the
average across individuals being 32% (SD 74%). The
rmANOVA did not show any signiﬁcant change in [
11C]-
palmitate uptake after VLCD (Fig. 3, main effect of repe-
tition: P  0.712, repetition  region interaction: P 
0.676). The change in [
18F]-FTHA uptake versus change in
[
11C]-palmitate correlated positively in all brain areas, and
all of the correlations were statistically signiﬁcant. For the
hypothalamus, the correlation r value was 0.56 (P  0.05).
Fatty acid uptake and metabolic characteristics.
Brain fatty acid uptake measured with [
18F]-FTHA-PET
was positively associated with age (P  0.007, r  0.52),
fasting serum insulin (P  0.05, r  0.40) and homeostasis
model assessment (HOMA) index (P  0.04, r  0.41) (Fig.
4). The correlation between [
18F]-FTHA and age persisted
after the data were adjusted for BMI (P  0.03, r  0.46).
Both total and nonoxidized fraction of fatty acid uptake
were positively associated with the BMI (total: P  0.002,
nonoxidized: P  0.004).
DISCUSSION
To our knowledge, this is the ﬁrst study to investigate
brain FFA uptake in obese patients with MS. The main
ﬁnding of the study is that patients with MS have higher
FFA uptake in the brain compared with healthy subjects.
Weight loss reduced FFA uptake more in healthy subjects,
and this was more due to decreased FFA oxidation rather
than decreased metabolic FFA utilization.
We and others have previously used [
18F]-FTHA and
PET to quantify regional FFA metabolism, especially in
myocardium and skeletal muscle (18,20,21). Recently we
showed that [
18F]-FTHA accumulates in the brain in sig-
niﬁcant amounts (18), thus making it a reliable tracer to
quantify brain FFA uptake. The brain tissue-input ratio for
[
18F]-FTHA ratio was high, suggesting that [
18F]-FTHA
crosses the blood-brain barrier and accumulates persis-
tently and in measurable amounts. More than half of the
tracer was going into the lipids, and less than half into the
breakdown products (18). These breakdown products
likely represent oxidation, so the study results suggest that
[
18F]-FTHA reﬂects total uptake. [
11C]-palmitate has been
shown to accumulate in monkey brain (9) and the ex-
tracted fraction is independent of cerebral ﬂow (22).
Palmitate accumulation in the brain has also been veriﬁed
in rats (11,23–25), and the ﬂux is proportional to published
values for regional brain oxidative metabolism (23). Long-
chain saturated fatty acids such as [
11C]-palmitate enter, to
a large extent (50–60%), via -oxidation in mitochondria,
creating radioactive, aqueous metabolites, particularly glu-
tamate, glutamine, and aspartate, whereas the other half is
incorporated into lipids (22,26,27). After the fast oxidation
of [
11C]-palmitate, the remaining radioactivity thus enters
the stable lipid pool of the brain representing nonoxidative
residual. It has been suggested that 83% of brain radioac-
tivity is in stable compartments within 2 min after a
steady-state level of plasma palmitate is achieved (9).
Plasma [
11C]-palmitate activity in our study was stable
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FIG. 2. Left: Baseline brain white and gray matter uptake rates of [
18F]-FTHA (A) and [
11C]-palmitate (B). P values were calculated using Student
t test. *P value of 0.01; **P value of 0.0006. NS, not signiﬁcant. White bars, healthy; black bars, MS. Right: Transaxial, coronal, and sagittal
sections of group-wise [
18F]-FTHA-PET and [
11C]-palmitate-PET images of the brain in healthy controls (A and C) and MS patients (B and D). A:
[
18F]-FTHA-PET healthy control. B:[
18F]-FTHA PET MS. C:[
11C]-palmitate-PET healthy control. D:[
11C]-palmitate-PET MS. Images represent
average spatially normalized uptake images, and the scale is mmol/(100g  min). In the PET images, the highest activity is shown in red as an
index of tracer accumulation. The difference between [
18F]-FTHA and [
11C]-palmitate is that [
18F]-FTHA is metabolically trapped whereas
[
11C]-palmitate is not. Higher activity of [
18F]-FTHA reﬂects the accumulation of the tracer in the brain tissue. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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was done using time frames of 10–20 min, the palmitate
results from brain can be considered to represent incor-
poration to stable compartments, and thus the so-called
nonoxidative residual. We speculate that by combining the
information from [
18F]-FTHA and [
11C]-palmitate, it may
be possible to estimate the brain FFA oxidative compo-
nent as the difference between total and nonoxidative fatty
acid uptake ([
18F]-FTHA minus [
11C]-palmitate). From our
in vivo validation study, we found that both [
13C]-palmitate
and [
18F]-FTHA are incorporated into the brain in measur-
able amounts. The percentage found in the brain hydro-
philic and lipid pool did not differ between tracers,
whereas a difference was seen in distribution within the
lipid pool. From both tracers, we found that more than 60%
were found in the lipid pool; [
18F]-FTHA was mainly in
triglycerides, whereas [
13C]-palmitate was mainly recov-
ered from phospholipids. The conversion of [
18F]-FTHA to
phospholipids might be different because of steric or
charge hindrance. However, the in vivo validation was to
show that both tracers are stored in the brain in similar
amounts. The distribution of tracers within lipid pool itself
is not addressed since PET cannot distinguish between
these storage forms.
The brain uptake of [
18F]-FTHA and [
11C]-palmitate was
increased in patients with MS compared with healthy
individuals. The difference with [
18F]-FTHA was not uni-
formly increased in all brain areas. The total FFA uptake
was signiﬁcantly greater in the white matter among sub-
jects with MS compared with healthy controls, and the
increment appeared to be of larger magnitude than that in
the gray matter. The increase in white matter [
18F]-FTHA
uptake could contribute to previous ﬁndings of brain white
matter expansion among obese subjects (28). The differ-
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FIG. 3. Left: Graphs show the results of brain white and gray matter uptake of [
18F]-FTHA and [
11C]-palmitate in the MS group before and after
VLCD. P values were calculated using paired Student t test. *P value < 0.02; **P value of 0.009; NS, not signiﬁcant; black bars, before VLCD; white
bars, after VLCD. Right: Results from the voxel-based mapping analysis. Results are rendered on an anatomical brain model; red areas illustrate
brain regions where [
18F]-FTHA uptake was signiﬁcantly reduced after dieting among MS patients (Tmax  4.21 at (66, 22, 48), kE  161,315,
cluster-level corrected P < 0.0005). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 4. The brain uptake of [
18F]-FTHA representing total brain FFA uptake positively correlated with fasting insulin (P < 0.05; r  0.40) and
age (P  0.007; r  0.52). Fasting insulin values are taken from OGTT.
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11C]-palmitate between groups was more uni-
form and thus statistically signiﬁcant in all analyzed areas.
The hypothalamic area, now associated with fatty acid
sensing and regulation of energy balance and feeding (2,4),
had also increased uptake of both [
11C]-palmitate and
[
18F]-FTHA. Weight loss reduced the [
18F]-FTHA uptake
uniformly in all brain regions, including the hypothalamus.
It is hypothesized that reduced [
18F]-FTHA uptake simul-
taneously with no change in [
11C]-palmitate uptake might
reﬂect reduction in brain FFA oxidative component. This
result is in line with a recent rodent study in which
inhibition of hypothalamic -oxidation normalized the
energy homeostasis of the animals (5). Thus, the changes
in the oxidative component seem to be related more to
weight control and satiety, supporting our ﬁnding that
oxidative metabolism is different in the obese MS group
and could be partially reversed by weight loss. There was
no statistically signiﬁcant difference in nonoxidative stor-
age component after weight loss, but the change in [
11C]-
palmitate uptake was highly variable between individuals.
The reason why a decrease was seen in [
18F]-FTHA uptake
but not in [
11C]-palmitate could be that oxidative metabo-
lism might be more ﬂexible in nature, whereas the synthe-
sis of complex lipids may be more preserved due to its
important structural role in the brain. In addition, these
studies were conducted under fasting conditions, which
are characterized by activation of FFA oxidative metabo-
lism. This may also help explain why intervention-related
differences in this process are more easily identiﬁed than
those in storage. The dieting period did not affect fasting
plasma FFA levels, thus multiplying image data with
individual FFA level does not contribute to the observed
decrease in FFA uptake.
Our ﬁndings are consistent with recent studies implicat-
ing the role of hypothalamic fatty acid sensing and their
role in the regulation of feeding, energy balance (2,4,5),
and peripheral physiologic processes (29). The normaliza-
tion of hypothalamic lipid sensing has been linked to
normalization of energy and glucose homeostasis (5).
From our study results, it seems that the normal catabolic
effect of central FFAs is disturbed in obesity, and this is at
least partially reversible after weight loss. Peripheral insu-
lin resistance contributing to MS could also affect the
brain. In healthy pigs, hyperinsulinemia induced 20–50%
decrease in brain [
18F]-FTHA radioactivity compared with
fasting state (18). The hypothesized central insulin resis-
tance could interfere with brain glucose utilization, thus
resulting in compensatory increased FFA uptake and FFA
oxidation. Weight loss is known to improve insulin sensi-
tivity and plasma lipid proﬁle (30). The beneﬁcial effect of
weight loss was observed in our study among MS patients;
in addition to beneﬁcial peripheral effects, FFA uptake in
the brain was uniformly decreased due to a decrease in
FFA oxidation. The correlations from our study corrobo-
rate this line of interference: FFA uptake was positively
correlated with BMI, plasma insulin, and HOMA-index;
among these, BMI had the strongest correlation. Brain
FFA uptake also increased with ageing, suggesting that
ageing is related to degenerative changes in the metabolic
processes, and reinforcing the theory that age is a risk
factor for MS.
Given that the activation of hypothalamic nuclei can
result in changes in sympathetic tone, and that hypothal-
amus is a key regulator in feeding and energy balance, it is
interesting to hypothesize that central FFAs could contrib-
ute to increased sympathetic tone in obesity. Previous
studies support both positive and negative effects of
central lipids in sympathetic tone. It has been reported
that central lipid infusion resulting in increased brain
lipids might modulate sympathoadrenal response (31), and
that intracerebrovascular infusion of fatty acids might
lower sympathetic activity. Unfortunately, we did not have
any direct measurements to address this question.
Limitations in this study were the small number of
subjects in the healthy control group and the fact that all
of the healthy subjects were males. If sex is used in the
statistical model as a covariate, the group difference in
[
18F]-FTHA uptake persists in the white matter (group 
region: F  6.72, P  0.007; main effect of group in the
white matter: F  4.92, P  0.037), but not in other brain
regions, and no signiﬁcant effects are seen with [
18F]-
palmitate. In addition, female patients with MS had higher
uptake values for both radioligands than male patients
with MS. Future studies including healthy females should
establish whether a signiﬁcant interaction exists between
sex and disease status, such that female patients may be
more severely affected than male patients, as current data
suggest. However, we think that a simple confounding
main effect of sex is unlikely to explain the current results,
based on three facts. First, [
18F]-FTHA uptake is increased
in MS in white matter even when sex is taken into account.
Second, signiﬁcant correlations were seen between fatty
acid uptake and clinical variables, such as BMI and fasting
plasma glucose, suggesting that increased fatty acid up-
take is more likely related to metabolic abnormalities than
sex alone. Third, the signiﬁcant decrease in fatty acid
uptake after weight loss argues against a main effect of sex
because such main effect would not be reversible. Never-
theless, we acknowledge the skewed sex distribution as a
limitation to the interpretation of the results, and recom-
mend that sex be taken into account in future studies. The
number of subjects having MS differs in cross-section
versus VLCD intervention. The ﬁrst phase of the study was
only cross-sectional. After having positive results from
phase 1, we wanted to study in more detail the possibility
that brain FFA uptake is related to weight. The more
comprehensive phase two (VLCD intervention) was intro-
duced in the study protocol and the last 16 of 23 subjects
took part in this phase. Another limiting factor is that the
brain kinetics of [
18F]-FTHA is not known so well as in
other organs and was assumed to be taken up as natural
palmitate. Although the in vivo biodistribution of [
18F]-
FTHA in the brain suggests that [
18F]-FTHA represents
total uptake, it does not prove that it equals uptake of
natural FFAs. In our study, the total oxidation of [
11C]-
palmitate was found to be less than 50%. In the animal
studies, it has been found that approximately 60% of the
[
11C]-palmitate enters to -oxidation (9). It is possible that
the kinetic properties of [
18F]-FTHA differ slightly from
our assumption, explaining the slight difference between
our study and animal studies. Nevertheless, this would not
affect the differences found between the two groups. The
dosages of injected tracers did not explain the ﬁndings,
even when weight was taken into account. In addition, the
isocaloric diet was not controlled, but the subjects were
free to eat what they wanted. So the quality and quantity of
the foods probably differ between subjects.
To conclude, we have found that patients fulﬁlling the
International Diabetes Federation criteria of metabolic
syndrome have increased brain FFA uptake when com-
pared with healthy subjects. Weight loss is able to partly
reverse this abnormality. These novel ﬁndings highlight
BRAIN FATTY ACID UPTAKE IN METABOLIC SYNDROME
2176 DIABETES, VOL. 59, SEPTEMBER 2010 diabetes.diabetesjournals.orgthe possible role of brain FFAs in regulation of body
weight. It seems that the normal catabolic effect of central
FFAs is disturbed in MS and this is partially reversed after
weight loss.
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